Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Phase IV Website Planned For October 2001; Final Tracking Rule Issued

Executive Summary

FDA plans to launch a website on the status of pharmaceutical company Phase IV commitments by Oct. 1, 2001.
Advertisement

Related Content

PDUFA III Authorizes FDA To Alert MDs To Failed Phase IV Commitments
PDUFA III Authorizes FDA To Alert MDs To Failed Phase IV Commitments
Phase IV study commitments pending
Phase IV study commitments pending
Postmarketing Study Status Will Be Defined By Trial Making Least Progress
Postmarketing Study Status Will Be Defined By Trial Making Least Progress
FDA Antiviral Division's Jolson Will Be Acting ORM Director Starting Nov. 6
FDA Antiviral Division's Jolson Will Be Acting ORM Director Starting Nov. 6
Postmarketing Study End Of Usefulness Must Be Confirmed By FDA
Postmarketing Study End Of Usefulness Must Be Confirmed By FDA
Advertisement
UsernamePublicRestriction

Register

PS036813

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel